Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterates a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintains a price target of $88.
June 17, 2024 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on CRISPR Therapeutics and maintained a price target of $88.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100